Physician profile
Dale E Merrell
NPI 1871585885
$2,069.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $291 · 2021: $45.27 · 2022: $13.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.32 | 2019-2020 | |
| Gilead Sciences, INC. | $329.36 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.84 | 2019-2020 | |
| Janssen Biotech, INC. | $145.14 | 2019-2020 | |
| Shionogi INC | $105.77 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $96.65 | 2019 | |
| Pfizer INC. | $80.05 | 2019 | |
| Merck Sharp & Dohme LLC | $48.82 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $46.46 | 2019 | |
| Ucb, INC. | $36.22 | 2019 | |
| Shire North American Group INC | $31.25 | 2019 | |
| Daiichi Sankyo INC. | $22.91 | 2019 | |
| Boston Scientific Corporation | $18.03 | 2021 | |
| Ethicon US, LLC | $16.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.82 | 2019 | |
| Romark Laboratories, Lc | $13.33 | 2019 | |
| Medtronic, INC. | $11.47 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.